Navigation Links
Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement
Date:9/19/2007

Adams Seeks to Develop New Prescription Adult Cough Products Using

Lipocine's Proprietary Lip'ral(TM) Technologies

CHESTER, N.J. and SALT LAKE CITY, Sept. 19 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. (Nasdaq: ARxT) and Lipocine Inc., a privately- held, leading drug delivery company that uses clinically validated proprietary technologies to address key unmet drug delivery and therapeutics needs, today announced that they have entered into a license and collaboration agreement to develop new prescription adult cough products.

Commenting on the agreement, COO Robert D. Casale said, "This collaboration with Lipocine provides Adams with access to an additional proprietary platform technology and fits with our strategy of taking established compounds and adding increased functionality to create patent- protected, value-added products. The products developed through this collaboration could offer doctors a non-narcotic prescribing option to treat cough with an enhanced dosing regimen. In addition, these products will help Adams compete in the $1.1 billion prescription cough and cold market in the United States."

"Given the large and growing size of the respiratory market, and how patients can benefit from enhanced dosage forms and regimens, we are very pleased to partner with Adams, a company highly respected for its commercialization accomplishments," said Dr. Mahesh Patel, president and CEO of Lipocine Inc.

Lip'ral(TM) and Lip'ral(TM)-SSR are clinically proven oral delivery technologies for water insoluble drugs that improve absorption and can be extended to enable controlled release of insoluble drugs and drugs with pH- sensitive solubility. Multiple patents h
'/>"/>

SOURCE Adams Respiratory Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. NanoRite Innovation Center opens with small science, big promise
3. UW-Madison to receive $125M for bioenergy research center
4. WARF enters licensing agreements for stem cell products
5. Internet-enabled niche markets take center stage
6. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
7. TomoTherapy opens technical training center
8. Stem cell and regenerative medicine center to aid education and commerce
9. Mega-Metro Center may go beyond Chicago and Wisconsin
10. Software company enters health space with RFID solutions on hold
11. Former Fiserv exec to enter Business Hall of Fame
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of innovative therapies ... today announced that it will release fourth quarter ... on Monday, March 9th, 2015. AcelRx management will ... Eastern Time (1:30 p.m. Pacific Time) on March ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... de Paris in December 2011, ... study of yttrium-90 resin microspheres versus sorafenib in advanced ... results expected late 2016.   SARAH, a ... liver cancer (hepatocellular carcinoma, or HCC) has completed patient ...
(Date:3/3/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... Miami, FL on March 10, 2015 at 1:05 ... Financial Officer, will provide a corporate overview. The ... corporate website at www.halozyme.com , and a recording will ... access the live webcast, please log on to Halozyme,s website ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... the "Gene Therapy Market, 2015 - 2025" ... Therapy Market, 2015-2025" report provides an extensive study on ... research has been carried out in this field for ... therapies (four available in Asian markets; one approved in ...
Breaking Biology Technology:AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7
... GERMANTOWN, Maryland and HILDEN, Germany ... QGEN ; Frankfurt , Prime Standard:,QIA) today announced ... Institute,for Product Quality (ifp), pursuant to which QIAGEN has ... by the Berlin -based specialized,laboratory center for food ...
... ... and industry leaders from around the globe to discuss pain management, preclinical and clinical development ... ... Pain Therapeutics Summit , set to take place on October 4th-5th, 2010 in Philadelphia, has ...
... , May 25 Regado Biosciences, Inc., ... aptamers with active control agents, today announced issuance of ... new patent includes coverage for RB007, the modulator or ... REG1 and REG2 anticoagulation systems.  The allowed claims in ...
Cached Biology Technology:QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 2QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 3QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 4QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 5QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 6QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 7Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit 2Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems 2Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems 3
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... Conn. , Jan. 26, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... new corporate website ( http://www.nxt-id.com/ ) as part of ... smart wallet. The Company launched its new consumer website ... Gino Pereira , CEO of NXT-ID said, "Our new ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... may not be the only organisms endangered by some food ... health risks to humans who eat meat from chickens that ... the April 9 issue of Chemical & Engineering News, the ... Roxarsone, the most common arsenic-based additive used in chicken feed, ...
... As people age, they may have to exercise even harder ... suggestion of a report in the February issue of the ... signal that gives muscles a kind of metabolic boost in ... researchers found that so-called AMP-activated protein kinase (AMPK) slows down ...
... to repair the human body, replacing defective and worn ... the body does not always accept such substitutes seamlessly. ... simply changing the surface texture of implants can dramatically ... materials. , Two recent experiments have focused on ...
Cached Biology News:Power-boosting signal in muscle declines with age 2Nanotextured implant materials: blending in, not fighting back 2Nanotextured implant materials: blending in, not fighting back 3
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... 20-HETE is a cytochrome P450 (CYP450) metabolite ... the renal and cerebral vasculature. In rat ... mediates pressure-induced autoregulatory vasoconstriction. 20-HETE is excreted ... of free 20-HETE (20-40 pg/ml in human ...
... GPS-M Mutagenesis System enables you to insert ... into,your target DNA by in vitro transposition. ... Tn7-based,transposon randomly into the DNA target. Target ... or purified,chromosomal DNA, depending on your interests ...
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: